Pharmacokinetics of the P-gp Inhibitor Tariquidar in Rats After Intravenous, Oral, and Intraperitoneal Administration
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pharmacokinetics of the P-gp Inhibitor Tariquidar in Rats After Intravenous, Oral, and Intraperitoneal Administration
Authors
Keywords
-
Journal
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS
Volume -, Issue -, Pages -
Publisher
Springer Nature
Online
2018-04-03
DOI
10.1007/s13318-018-0474-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Molecular Imaging of ABCB1 and ABCG2 Inhibition at the Human Blood–Brain Barrier Using Elacridar and11C-Erlotinib PET
- (2017) Remy B. Verheijen et al. JOURNAL OF NUCLEAR MEDICINE
- Pilot PET Study to Assess the Functional Interplay Between ABCB1 and ABCG2 at the Human Blood-Brain Barrier
- (2016) M Bauer et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Whole-Body Distribution and Radiation Dosimetry of 11C-Elacridar and 11C-Tariquidar in Humans
- (2016) M. Bauer et al. JOURNAL OF NUCLEAR MEDICINE
- Strategies to Inhibit ABCB1- and ABCG2-Mediated Efflux Transport of Erlotinib at the Blood–Brain Barrier: A PET Study on Nonhuman Primates
- (2016) Nicolas Tournier et al. JOURNAL OF NUCLEAR MEDICINE
- Clinical pharmacokinetics of an amorphous solid dispersion tablet of elacridar
- (2016) Emilia Sawicki et al. Drug Delivery and Translational Research
- Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine, or docetaxel in children and adolescents with refractory solid tumors
- (2015) Elizabeth Fox et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Approaching Complete Inhibition of P-Glycoprotein at the Human Blood–Brain Barrier: An (R)-[11C]Verapamil PET Study
- (2015) Martin Bauer et al. JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM
- Increased Permeability-Glycoprotein Inhibition at the Human Blood-Brain Barrier Can Be Safely Achieved by Performing PET During Peak Plasma Concentrations of Tariquidar
- (2014) W. C. Kreisl et al. JOURNAL OF NUCLEAR MEDICINE
- Quantification of Gastrointestinal Liquid Volumes and Distribution Following a 240 mL Dose of Water in the Fasted State
- (2014) Deanna M. Mudie et al. MOLECULAR PHARMACEUTICS
- Bile salts enhance the intestinal absorption of lipophilic drug loaded lipid nanocarriers: Mechanism and effect in rats
- (2013) Zhiwen Zhang et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Interaction of 11C-Tariquidar and 11C-Elacridar with P-Glycoprotein and Breast Cancer Resistance Protein at the Human Blood-Brain Barrier
- (2013) M. Bauer et al. JOURNAL OF NUCLEAR MEDICINE
- Development and Evaluation of a Novel Microemulsion Formulation of Elacridar to Improve its Bioavailability
- (2013) Ramola Sane et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- A Novel PET Protocol for Visualization of Breast Cancer Resistance Protein Function at the Blood–Brain Barrier
- (2012) Thomas Wanek et al. JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM
- Pharmacokinetics of Single Ascending Doses of the P-Glycoprotein Inhibitor Tariquidar in Healthy Subjects
- (2012) M. Bauer et al. PHARMACOLOGY
- Pgp-Mediated Interaction Between (R)-[11C]Verapamil and Tariquidar at the Human Blood–Brain Barrier: A Comparison With Rat Data
- (2011) M Bauer et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- The third-generation P-glycoprotein inhibitor tariquidar may overcome bacterial multidrug resistance by increasing intracellular drug concentration
- (2011) I. Leitner et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- The “Specific” P-Glycoprotein Inhibitor Tariquidar Is Also a Substrate and an Inhibitor for Breast Cancer Resistance Protein (BCRP/ABCG2)
- (2010) Pavitra Kannan et al. ACS Chemical Neuroscience
- A Pharmacodynamic Study of Docetaxel in Combination with the P-glycoprotein Antagonist Tariquidar (XR9576) in Patients with Lung, Ovarian, and Cervical Cancer
- (2010) R. J. Kelly et al. CLINICAL CANCER RESEARCH
- A Phase I Study of the P-Glycoprotein Antagonist Tariquidar in Combination with Vinorelbine
- (2009) J. Abraham et al. CLINICAL CANCER RESEARCH
- Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[11C]verapamil PET
- (2009) Claudia Kuntner et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- A regulatory viewpoint on transporter-based drug interactions
- (2008) L. Zhang et al. XENOBIOTICA
- Measurements of rat and mouse gastrointestinal pH, fluid and lymphoid tissue, and implications for in-vivo experiments
- (2007) Emma L. McConnell et al. JOURNAL OF PHARMACY AND PHARMACOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search